Diversity of HLA-A2-Restricted and Immunodominant Epitope Repertoire of Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Protein: Novel Insights among N-Terminal, Central and C-Terminal Regions

Biomolecules. 2023 Mar 16;13(3):545. doi: 10.3390/biom13030545.

Abstract

The present study sought to search for the immunodominance related to the N-terminal, Central and C-terminal regions of HTLV-1 Tax using novel, cutting-edge peptide microarray analysis. In addition, in silico predictions were performed to verify the presence of nine amino acid peptides present along Tax restricted to the human leukocyte antigen (HLA)-A2.02*01 haplotype, as well as to verify the ability to induce pro-inflammatory and regulatory cytokines, such as IFN-γ and IL-4, respectively. Our results indicated abundant dose-dependent reactivity for HLA-A*02:01 in all regions (N-terminal, Central and C-terminal), but with specific hotspots. Furthermore, the results of fold-change over the Tax11-19 reactivity obtained at lower concentrations of HLA-A*02:01 reveal that peptides from the three regions contain sequences that react 100 times more than Tax11-19. On the other hand, Tax11-19 has similar or superior HLA-A*02:01 reactivity at higher concentrations of this haplotype. The in silico analysis showed a higher frequency of IFN-γ-inducing peptides in the N-terminal portion, while the C-terminal portion showed a higher frequency of IL-4 inducers. Taken together, these results shed light on the search for new Tax immunodominant epitopes, in addition to the canonic Tax11-19, for the rational design of immunomodulatory strategies for HTLV-1 chronic diseases.

Keywords: CD8+ T-cell response; HLA-A2 haplotype; HTLV-1; MHC-I peptides; Tax; immunodominance; immunoinformatics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Gene Products, tax / genetics
  • HLA-A2 Antigen
  • Human T-lymphotropic virus 1* / genetics
  • Humans
  • Immunodominant Epitopes
  • Interleukin-4
  • Peptides
  • T-Lymphocytes, Cytotoxic

Substances

  • HLA-A2 Antigen
  • Immunodominant Epitopes
  • Gene Products, tax
  • Interleukin-4
  • Peptides

Grants and funding

This research was funded by CNPq (312538/2021-9 and 407779/2021-3), FAPEMIG (APQ-01499-21) and CAPES (fellowships). T.A.P.-S. and Á.L.-R. received CAPES fellowship; L.C.C.-D. received FAPEMIG fellowship; P.M.-O. received PIBITI/CNPq and PROBIC/FAPEMIG fellowships; J.G.A.C.-d.-R., F.G.d.F. and E.F.B.-S. received Pq CNPq senior fellowships.